Filter Results
:
(231)
Show Results For
-
All HBS Web
(503)
- Faculty Publications (231)
Show Results For
-
All HBS Web
(503)
- Faculty Publications (231)
Page 1 of
231
Results
→
- March 2024
- Case
Biomanufacturing Decentralization by Stämm
By: Paul A. Gompers, Jenyfeer Martínez Buitrago and Mariana Cal
Stämm, a startup based on decentralizing biomanufacturing processes, is transitioning to product launch. The founders face key challenges to craft the startup’s business model and growth strategy, as well as to choose the optimal model for scaling their technological...
View Details
- February 2024 (Revised March 2024)
- Teaching Note
X: The Foghorn Decision
By: Kyle Myers and Walter Frick
Teaching Note for HBS Case No. 618-060.
View Details
Keywords:
Alternative Energy;
Energy Generation;
Energy Sources;
Climate Change;
Green Technology;
Selection and Staffing;
Collaborative Innovation and Invention;
Disruptive Innovation;
Independent Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Knowledge;
Product Design;
Product Development;
Research and Development;
Risk and Uncertainty;
Science-Based Business;
Auto Industry;
Auto Industry;
Auto Industry;
Auto Industry;
Auto Industry;
Auto Industry;
Auto Industry
- November 2023 (Revised April 2024)
- Case
BiomX: Bringing Phage Back to the Stage
By: Paul A. Gompers, Elie Ofek, Orna Dan and Emilie Billaud
In the spring of 2023, and following the favorable results of a trial involving its phage cocktail for treating lung infections among cystic fibrosis (CF) patients, the leadership of BiomX had several critical issues to wrestle with. First, given its precarious...
View Details
Keywords:
Working Capital;
Financing and Loans;
Health Testing and Trials;
Product Development;
Research and Development;
Science-Based Business;
Commercialization;
Biotechnology Industry;
Biotechnology Industry
Gompers, Paul A., Elie Ofek, Orna Dan, and Emilie Billaud. "BiomX: Bringing Phage Back to the Stage." Harvard Business School Case 524-051, November 2023. (Revised April 2024.)
- September 2023 (Revised December 2023)
- Case
TetraScience: Noise and Signal
By: Thomas R. Eisenmann and Tom Quinn
In 2019, TetraScience CEO “Spin” Wang needed advice. Five years earlier, he had cofounded a startup that saw early success with a hardware product designed to help laboratory scientists in the biotechnology and pharmaceutical spaces more easily collect data from...
View Details
Keywords:
Entrepreneurship;
Business Growth and Maturation;
Business Organization;
Restructuring;
Forecasting and Prediction;
Digital Platforms;
Analytics and Data Science;
AI and Machine Learning;
Organizational Structure;
Network Effects;
Competitive Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States;
Boston
- June 2023
- Case
Verve Therapeutics: Taking DNA Editing to Heart
By: Shikhar Ghosh and Shweta Bagai
Verve Therapeutics, a public biotech company based in Boston, created a novel approach to addressing cardiovascular disease (CVD) - a leading cause of deaths globally. The company's approach was a single shot treatment to permanently lower cholesterol, thus reducing...
View Details
Keywords:
AI;
Genetic Engineering;
Medicine;
Health Care and Treatment;
Genetics;
Innovation Strategy;
Business and Stakeholder Relations;
Medical Specialties;
Innovation and Invention;
Entrepreneurship;
Biotechnology Industry
Ghosh, Shikhar, and Shweta Bagai. "Verve Therapeutics: Taking DNA Editing to Heart." Harvard Business School Case 823-113, June 2023.
- April 2023
- Case
Drive Capital: A New Road for Venture
By: Paul A. Gompers and Alicia Dadlani
Founded by two former Sequoia Capital partners, Columbus-Ohio-based Drive Capital’s mission was to build a world-class venture capital firm in the middle of the U.S., an area historically overlooked by VCs. Drive faced early challenges of attracting investors, sourcing...
View Details
Keywords:
Venture Capital;
Business Startups;
Entrepreneurship;
Investment;
Business Strategy;
Financial Services Industry;
Financial Services Industry;
United States;
Ohio
Gompers, Paul A., and Alicia Dadlani. "Drive Capital: A New Road for Venture." Harvard Business School Case 823-056, April 2023.
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19....
View Details
- January 2023
- Case
Vertex and the Cure for Type 1 Diabetes
By: Amitabh Chandra, William J Anderson and Silvia Mare
Keywords:
Biotechnology Industry
- October 2022 (Revised May 2023)
- Case
Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues
Ginkgo Bioworks, a synthetic biology company based in Boston, Massachusetts, faced divergent views on its revenue possibilities and accounting practices. After a report emerged accusing it of fraudulent accounting and lack of innovation, its share price plunged. But...
View Details
Keywords:
Fraud Allegations;
Revenue;
Reports;
Accounting Audits;
Innovation and Management;
Investment;
Biotechnology Industry;
Boston
Dey, Aiyesha, Jonas Heese, Suraj Srinivasan, and Annelena Lobb. "Ginkgo Bioworks vs. Scorpion Capital: The Debate Over Related-Party Revenues." Harvard Business School Case 123-037, October 2022. (Revised May 2023.)
- March 2022
- Teaching Note
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008.
View Details
Keywords:
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information Technology;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Technology Adoption;
Biotechnology Industry;
Biotechnology Industry;
United States;
California;
Puerto Rico;
Rhode Island
- Article
Internal Deadlines, Drug Approvals, and Safety Problems
By: Lauren Cohen, Umit Gurun and Danielle Li
Absent explicit quotas, incentives, reporting, or fiscal year-end motives, drug approvals around the world surge in December, at month-ends, and before respective major national holidays. Drugs approved before these informal deadlines are associated with significantly...
View Details
Keywords:
Health;
Economics;
Government and Politics;
Innovation and Invention;
Research;
Science;
Biotechnology Industry;
Biotechnology Industry;
Biotechnology Industry
Cohen, Lauren, Umit Gurun, and Danielle Li. "Internal Deadlines, Drug Approvals, and Safety Problems." American Economic Review: Insights 3, no. 1 (March 2021): 67–82.
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is...
View Details
Keywords:
Digital Technologies;
Change;
Change Management;
Decision Making;
Cost vs Benefits;
Decisions;
Information;
Analytics and Data Science;
Innovation and Invention;
Innovation and Management;
Innovation Leadership;
Innovation Strategy;
Technological Innovation;
Jobs and Positions;
Knowledge;
Leadership;
Organizational Culture;
Science;
Strategy;
Information Technology;
Technology Adoption;
Biotechnology Industry;
Biotechnology Industry;
United States;
California;
Puerto Rico;
Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- January 2021
- Case
Takeda Pharmaceutical Company Limited (A)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case follows Christophe Weber, President and CEO of Takeda Pharmaceutical Company Limited, a leading pharmaceutical company headquartered in Tokyo, Japan, as Takeda considers acquiring Shire Plc, a biotech company based in Ireland. The acquisition would turn...
View Details
Keywords:
Pharmaceutical Companies;
Pharmaceuticals;
Biotech;
Biotechnology;
M&A;
Mergers & Acquisitions;
R&D;
Talent Management;
Mergers and Acquisitions;
Globalization;
Management;
Global Strategy;
Talent and Talent Management;
Pharmaceutical Industry;
Pharmaceutical Industry;
Japan;
Asia
Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (A)." Harvard Business School Case 721-373, January 2021.
- January 2021
- Supplement
Takeda Pharmaceutical Company Limited (B)
By: David J. Collis, Nobuo Sato and Akiko Kanno
This case is a follow up to HBS Case No. 721-373, Takeda Pharmaceutical Company Limited (A). Following the events of the previous case, Takeda reached an agreement to acquire Ireland-based Shire Plc. The case follows some of the achievements and challenges Takeda and...
View Details
Keywords:
Pharmaceutical Companies;
Pharmaceuticals;
M&A;
Mergers & Acquisitions;
Biotech;
Biotechnology;
R&D;
Talent Management;
Mergers and Acquisitions;
Globalization;
Global Strategy;
Talent and Talent Management;
Strategy;
Biotechnology Industry;
Biotechnology Industry;
Japan;
Asia
Collis, David J., Nobuo Sato, and Akiko Kanno. "Takeda Pharmaceutical Company Limited (B)." Harvard Business School Supplement 721-374, January 2021.
- January 2021 (Revised June 2023)
- Case
Biobot Analytics
In 2017, Newsha Ghaeli and Mariana Matus were deciding whether to leave their labs at the Massachusetts Institute of Technology, put other job opportunities aside, and dive full-time into founding a wastewater analysis start-up, Biobot. Ghaeli, an architect, and Matus,...
View Details
Keywords:
Entrepreneurship;
Information Technology;
City;
Analytics and Data Science;
Personal Development and Career;
Technology Industry;
Technology Industry;
Technology Industry;
Technology Industry;
Technology Industry;
Technology Industry;
United States;
Kuwait;
Korean Peninsula
Kluender, Raymond, Joshua Krieger, and Mitchell Weiss. "Biobot Analytics." Harvard Business School Case 821-045, January 2021. (Revised June 2023.)
- November 2020
- Teaching Note
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
Teaching Note for HBS Case No. 221-031. When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA)...
View Details
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
- November 2020
- Case
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage...
View Details
Keywords:
Mergers and Acquisitions;
Value;
Valuation;
Judgments;
Decision Making;
Cash Flow;
Financial Instruments;
Cognition and Thinking;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Esty, Benjamin C., and Daniel Fisher. "Valuing Celgene's CVR." Harvard Business School Case 221-031, November 2020.
- October 2020 (Revised April 2022)
- Case
When Institutions Fail: HIV/AIDS in the 1980s
By: Tom Nicholas and Christian Godwin
During the early 1980s, young gay men in urban centers such as San Francisco and New York City began contracting a mysterious illness that would come to be known as HIV/AIDS. A diagnosis meant almost certain death, with a less than 1% survival rate. Conflicting...
View Details
Keywords:
Ethics;
Policy;
Government and Politics;
Health Pandemics;
History;
Rights;
Media;
Organizations;
Business and Community Relations;
Religion;
Social Psychology;
Identity;
Prejudice and Bias;
Social Issues;
Public Opinion;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States
Nicholas, Tom, and Christian Godwin. "When Institutions Fail: HIV/AIDS in the 1980s." Harvard Business School Case 821-002, October 2020. (Revised April 2022.)
- September 2020 (Revised January 2021)
- Case
Catalys Pacific
In 2019, BT Slingsby founds Catalys Pacific, the first biotech “venture creation” fund in Tokyo. After convincing some of the biggest Japanese pharmaceutical firms to invest, BT hopes the fund can make a big splash and transform biotechnology innovation in Japan. After...
View Details
Keywords:
Pharmaceutical Companies;
Biotech;
Health Care;
Entrepreneur;
Innovation;
International Business;
Entrepreneurial Finance;
Entrepreneurship;
Finance;
Innovation Strategy;
Venture Capital;
Strategy;
Cross-Cultural and Cross-Border Issues;
Pharmaceutical Industry;
Pharmaceutical Industry;
Tokyo
Krieger, Joshua Lev. "Catalys Pacific." Harvard Business School Case 821-035, September 2020. (Revised January 2021.)